Prosperity Financial Group Inc. Acquires 575 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Prosperity Financial Group Inc. boosted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 13.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,712 shares of the medical equipment provider’s stock after purchasing an additional 575 shares during the period. Prosperity Financial Group Inc.’s holdings in Lantheus were worth $422,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in LNTH. Geode Capital Management LLC lifted its stake in Lantheus by 2.0% in the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after acquiring an additional 32,551 shares during the last quarter. Massachusetts Financial Services Co. MA acquired a new stake in Lantheus in the third quarter valued at $25,955,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Lantheus by 47.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock valued at $1,041,000 after acquiring an additional 3,772 shares during the last quarter. Empirical Asset Management LLC acquired a new stake in Lantheus in the fourth quarter valued at $323,000. Finally, Focus Financial Network Inc. acquired a new stake in Lantheus in the fourth quarter valued at $292,000. Institutional investors own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on LNTH shares. Truist Financial raised their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. The Goldman Sachs Group started coverage on shares of Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price for the company. JMP Securities restated a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. Finally, StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $132.86.

Insider Activity at Lantheus

In other news, Director Mary Anne Heino sold 53,107 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by insiders.

Lantheus Stock Down 4.9 %

Shares of Lantheus stock opened at $104.62 on Wednesday. Lantheus Holdings, Inc. has a twelve month low of $56.44 and a twelve month high of $126.89. The company has a 50-day simple moving average of $91.13 and a two-hundred day simple moving average of $96.88. The stock has a market capitalization of $7.16 billion, a price-to-earnings ratio of 17.41 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.